Molecular basis of resistance to proteasome inhibitors in hematological malignancies

Drug Resistance Updates

Volumn 18, Issue , 2015, Pages 18-35

  Niewerth, Denise ^a   Jansen, Gerrit ^a   Assaraf, Yehuda G ^b   Zweegman, Sonja ^a   Kaspers, Gertjan J L ^a   Cloos, Jacqueline ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Bortezomib; Leukemia; Multiple myeloma; Proteasome inhibitor; Resistance

Indexed keywords

ABC TRANSPORTER B5; BORTEZOMIB; DELANZOMIB; DEXAMETHASONE; MARCKS PROTEIN; MULTIDRUG RESISTANCE PROTEIN; OPROZOMIB; PROTEASOME; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; X BOX BINDING PROTEIN 1; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

AGGRESOME; ARTICLE; AUTOPHAGY; BONE MARROW; CATALYSIS; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DNA POLYMORPHISM; ENZYME INHIBITION; HEMATOLOGIC MALIGNANCY; HUMAN; MICROENVIRONMENT; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; SIGNAL TRANSDUCTION; SURVIVAL; UNFOLDED PROTEIN RESPONSE; ANIMAL; DRUG RESISTANCE; HEMATOLOGIC NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DRUG RESISTANCE, NEOPLASM; HEMATOLOGIC NEOPLASMS; HUMANS; PROTEASOME INHIBITORS; PYRAZINES;

EID: 84922252107     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2014.12.001     Document Type: Article

References (210)

1. J. Abdi, L. Qiu, and H. Chang Micro-RNAs, new performers in multiple myeloma bone marrow microenvironment Biomark. Res. 2 2014 10
2. J. Adams The proteasome: a suitable antineoplastic target Nat. Rev. Cancer 4 2004 349 360
3. A.K. Agarwal, C. Xing, G.N. DeMartino, D. Mizrachi, M.D. Hernandez, A.B. Sousa, L. Martínez de Villarreal, H.G. dos Santos, and A. Garg PSMB8 encoding the β5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome Am. J. Hum. Genet. 87 2010 866 872
4. J.S. Ahn, S.H. Jung, D.H. Yang, S.Y. Bae, Y.K. Kim, H.J. Kim, and J.J. Lee Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma Clin. Lymphoma Myeloma Leuk. 14 2014 389 394
5. R.K. Amaravadi, J. Lippincott-Schwartz, X.-M. Yin, W.A. Weiss, N. Takebe, W. Timmer, R.S. DiPaola, M.T. Lotze, and E. White Principles and current strategies for targeting autophagy for cancer treatment Clin. Cancer Res. 17 2011 654 666
6. L. Ao, Y. Wu, D. Kim, E.R. Jang, K. Kim, D.M. Lee, K.B. Kim, and W. Lee Development of peptide-based reversing agents for P-glycoprotein-mediated resistance to carfilzomib Mol. Pharm. 9 2012 2197 2205
7. S. Arastu-Kapur, J.L. Anderl, M. Kraus, F. Parlati, K.D. Shenk, S.J. Lee, T. Muchamuel, M.K. Bennett, C. Driessen, A.J. Ball, and C.J. Kirk Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events Clin. Cancer Res. 17 2011 2734 2743
8. K. Arima, A. Kinoshita, H. Mishima, N. Kanazawa, T. Kaneko, T. Mizushima, K. Ichinose, H. Nakamura, A. Tsujino, A. Kawakami, M. Matsunaka, S. Kasagi, S. Kawano, S. Kumagai, K. Ohmura, T. Mimori, M. Hirano, S. Ueno, K. Tanaka, M. Tanaka, I. Toyoshima, H. Sugino, A. Yamakawa, K. Tanaka, N. Niikawa, F. Furukawa, S. Murata, K. Eguchi, H. Ida, and K.I. Yoshiura Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome Proc. Natl. Acad. Sci. U. S. A. 108 2011 14914 14919
9. B. Arnulf, H. Pylypenko, S. Grosicki, I. Karamanesht, X. Leleu, H. van de Velde, H. Feng, A. Cakana, W. Deraedt, and P. Moreau Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma Haematologica 97 2012 1925 1928
10. E.C. Attar, P.C. Amrein, J.W. Fraser, A.T. Fathi, S. McAfee, M. Wadleigh, D.J. Deangelo, D.P. Steensma, R.M. Stone, J. Foster, D. Neuberg, and K.K. Ballen Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) Leuk. Res. 37 2013 1016 1020
11. E.C. Attar, D.J. De Angelo, J.G. Supko, F. D'Amato, D. Zahrieh, A. Sirulnik, M. Wadleigh, K.K. Ballen, S. McAfee, K.B. Miller, J. Levine, I. Galinsky, E.G. Trehu, D. Schenkein, D. Neuberg, R.M. Stone, and P.C. Amrein Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia Clin. Cancer Res. 14 2008 1446 1454
12. E.C. Attar, J.L. Johnson, P.C. Amrein, G. Lozanski, M. Wadleigh, D.J. DeAngelo, J.E. Kolitz, B.L. Powell, P. Voorhees, E.S. Wang, W. Blum, R.M. Stone, G. Marcucci, C.D. Bloomfield, B. Moser, and R.A. Larson Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502 J. Clin. Oncol. 31 2013 923 929
13. C. Bachas, G.J. Schuurhuis, Y.G. Assaraf, Z.J. Kwidama, A. Kelder, F. Wouters, A.N. Snel, G.J. Kaspers, and J. Cloos The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse Leukemia 26 2012 1313 1320
14. P. Balsas, N. Lopez-Royuela, P. Galan-Malo, A. Anel, I. Marzo, and J. Naval Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis Biochem. Pharmacol. 77 2009 804 812
15. P. Balsas, P. Galan-Malo, I. Marzo, and J. Naval Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy Leuk. Res. 36 2012 212 218
16. M. Basler, M. Dajee, C. Moll, M. Groettrup, and C.J. Kirk Prevention of experimental colitis by a selective inhibitor of the immunoproteasome J. Immunol. 185 2010 634 641
17. J.R. Berenson, H.H. Yang, K. Sadler, S.G. Jarutirasarn, R.A. Vescio, R. Mapes, M. Purner, S. Lee, J. Wilson, B. Morrison, J. Adams, D. Schenkein, and R. Swift Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma J. Clin. Oncol. 24 2006 937 944
18. J.R. Berenson, H.H. Yang, R.A. Vescio, Y. Nassir, R. Mapes, S.P. Lee, J. Wilson, O. Yellin, B. Morrison, J. Hilger, and R. Swift Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up Ann. Hematol. 87 2008 623 631
19. J.R. Berenson, O. Yellin, T. Kazamel, J.D. Hilger, C.S. Chen, A. Cartmell, T. Woliver, M. Flam, E. Bravin, Y. Nassir, R. Vescio, and R.A. Swift A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma Leukemia 26 2012 1675 1680
20. C.E. Berndsen, and C. Wolberger New insights into ubiquitin E3 ligase mechanism Nat. Struct. Mol. Biol. 21 2014 301 307
21. A. Bertolotti, Y. Zhang, L.M. Hendershot, H.P. Harding, and D. Ron Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response Nat. Cell Biol. 2 2000 326 332
22. G. Bianchi, L. Oliva, P. Cascio, N. Pengo, F. Fontana, F. Cerruti, A. Orsi, E. Pasqualetto, A. Mezghrani, V. Calbi, G. Palladini, N. Giuliani, K.C. Anderson, R. Sitia, and S. Cenci The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition Blood 113 2009 3040 3049
23. C. Blackburn, K.M. Gigstad, P. Hales, K. Garcia, M. Jones, F.J. Bruzzese, C. Barrett, J.X. Liu, T.A. Soucy, D.S. Sappal, N. Bump, E.J. Olhava, P. Fleming, L.R. Dick, C. Tsu, M.D. Sintchak, and J.L. Blank Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit Biochem. J 430 2010 461 476
24. W. Blum, S. Schwind, S.S. Tarighat, S. Geyer, A.K. Eisfeld, S. Whitman, A. Walker, R. Klisovic, J.C. Byrd, R. Santhanam, H. Wang, J.P. Curfman, S.M. Devine, S. Jacob, C. Garr, C. Kefauver, D. Perrotti, K.K. Chan, C.D. Bloomfield, M.A. Caligiuri, M.R. Grever, R. Garzon, and G. Marcucci Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia Blood 119 2012 6025 6031
25. P. Cascio PA28αβ: the enigmatic magic ring of the proteasome? Biomolecules 4 2014 566 584
26. P. Cascio, M. Call, B.M. Petre, T. Walz, and A.L. Goldberg Properties of the hybrid form of the 26S proteasome containing both 19S and PA28 complexes EMBO J. 21 2002 2636 2645
27. L. Catley, E. Weisberg, T. Kiziltepe, Y.T. Tai, T. Hideshima, P. Neri, P. Tassone, P. Atadja, D. Chauhan, N.C. Munshi, and K.C. Anderson Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells Blood 108 2006 3441 3449
28. S. Cenci, A. Mezghrani, P. Cascio, G. Bianchi, F. Cerruti, A. Fra, H. Lelouard, S. Masciarelli, L. Mattioli, L. Oliva, A. Orsi, E. Pasqualetto, P. Pierre, E. Ruffato, L. Tagliavacca, and R. Sitia Progressively impaired proteasomal capacity during terminal plasma cell differentiation EMBO J. 25 2006 1104 1113
29. M.A. Chapman, M.S. Lawrence, J.J. Keats, K. Cibulskis, C. Sougnez, A.C. Schinzel, C.L. Harview, J.P. Brunet, G.J. Ahmann, M. Adli, K.C. Anderson, K.G. Ardlie, D. Auclair, A. Baker, P.L. Bergsagel, B.E. Bernstein, Y. Drier, R. Fonseca, S.B. Gabriel, C.C. Hofmeister, S. Jagannath, A.J. Jakubowiak, A. Krishnan, J. Levy, T. Liefeld, S. Lonial, S. Mahan, B. Mfuko, S. Monti, L.M. Perkins, R. Onofrio, T.J. Pugh, S.V. Rajkumar, A.H. Ramos, D.S. Siegel, A. Sivachenko, K. Stewart, S. Trudel, R. Vij, D. Voet, W. Winckler, T. Zimmerman, J. Carpten, J. Trent, W.C. Hahn, L.A. Garraway, M. Meyerson, E.S. Lander, G. Getz, and T.R. Golub Initial genome sequencing and analysis of multiple myeloma Nature 471 2011 467 472
30. D. Chauhan, L. Catley, G. Li, K. Podar, T. Hideshima, M. Velankar, C. Mitsiades, N. Mitsiades, H. Yasui, A. Letai, H. Ovaa, C. Berkers, B. Nicholson, T.H. Chao, S.T. Neuteboom, P. Richardson, M.A. Palladino, and K.C. Anderson A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib Cancer Cell 8 2005 407 419
31. D. Chauhan, A.V. Singh, M. Aujay, C.J. Kirk, M. Bandi, B. Ciccarelli, N. Raje, P. Richardson, and K.C. Anderson A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma Blood 116 2010 4906 4915
32. D. Chauhan, Z. Tian, B. Zhou, D. Kuhn, R. Orlowski, N. Raje, P. Richardson, and K.C. Anderson In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells Clin. Cancer Res. 17 2011 5311 5321
33. X. Chen, and S.A. Rotenberg PhosphoMARCKS drives motility of mouse melanoma cells Cell. Signal. 22 2010 1097 1103
34. V. Cheriyath, B.S. Jacobs, and M.A. Hussein Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors Drugs Res. Dev. 8 2007 1 12
35. N. Chondrogianni, F.L.L. Stratford, I.P. Trougakos, B. Friguet, A.J. Rivett, and E.S. Gonos Central role of the proteasome in senescence and survival of human fibroblasts: induction of a senescence-like phenotype upon its inhibition and resistance to stress upon its activation J. Biol. Chem. 278 2003 28026 28037
36. N. Chondrogianni, C. Tzavelas, A.J. Pemberton, I.P. Nezis, A.J. Rivett, and E.S. Gonos Overexpression of proteasome beta5 assembled subunit increases the amount of proteasome and confers ameliorated response to oxidative stress and higher survival rates J. Biol. Chem. 280 2005 11840 11850
37. A. Ciechanover Proteolysis: from the lysosome to ubiquitin and the proteasome Nat. Rev. Mol. Cell Biol. 6 2005 79 87
38. J. Cloos, D. Niewerth, and G. Jansen Pre-clinical studies on the molecular basis of bortezomib resistance and modalities to overcome resistance in hematological malignancies Q.P. Dou, Resistance to Proteasome Inhibitors in Cancer 2014 Springer International Publishing Switzerland 181 204
39. J. Cortes, D. Thomas, C. Koller, F. Giles, E. Estey, S. Faderl, G. Garcia-Manero, D. McConkey, S.L. Ruiz, R. Guerciolini, J. Wright, and H. Kantarjian Phase I study of bortezomib in refractory or relapsed acute leukemias Clin. Cancer Res. 10 2004 3371 3376
40. F. Cottini, A. Guidetti, C. Paba Prada, T. Hideshima, M. Maglio, D. Varga, D. Chauhan, J. Laubach, K.C. Anderson, and P.G. Richardson Resistance to proteasome inhibitors in multiple myeloma Q.P. Dou, Resistance to Proteasome Inhibitors in Cancer 2014 Springer International Publishing Switzerland 47 80
41. N.P. Dantuma, T.A. Groothuis, F.A. Salomons, and J. Neefjes A dynamic ubiquitin equilibrium couples proteasomal activity to chromatin remodeling J. Cell Biol. 173 2006 19 26
42. P. D'Arcy, S. Brnjic, M.H. Olofsson, M. Fryknäs, K. Lindsten, M. De Cesare, P. Perego, B. Sadeghi, M. Hassan, R. Larsson, and S. Linder Inhibition of proteasome deubiquitinating activity as a new cancer therapy Nat. Med. 17 2011 1636 1640
43. L.H. De Wilt, G. Jansen, Y.G. Assaraf, J. Van Meerloo, J. Cloos, A.D. Schimmer, E.T. Chan, C.J. Kirk, G.J. Peters, and F.A. Kruyt Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer Biochem. Pharmacol. 83 2012 207 217
44. S.D. Demo, C.J. Kirk, M.A. Aujay, T.J. Buchholz, M. Dajee, M.N. Ho, J. Jiang, G.J. Laidig, E.R. Lewis, F. Parlati, K.D. Shenk, M.S. Smyth, C.M. Sun, M.K. Vallone, T.M. Woo, C.J. Molineaux, and M.K. Bennett Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome Cancer Res. 67 2007 6383 6391
45. L.R. Dick, and P.E. Fleming Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy Drug Discov. Today 15 2010 243 249
46. M. Dimopoulos, D.S. Siegel, S. Lonial, J. Qi, R. Hajek, T. Facon, L. Rosinol, C. Williams, H. Blacklock, H. Goldschmidt, V. Hungria, A. Spencer, A. Palumbo, T. Graef, J.E. Eid, J. Houp, L. Sun, S. Vuocolo, and K.C. Anderson Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study Lancet Oncol. 14 2013 1129 1140
47. M.A. Dimopoulos, J.F. San-Miguel, and K.C. Anderson Emerging therapies for the treatment of relapsed or refractory multiple myeloma Eur. J. Haematol. 86 2011 1 15
48. W.X. Ding, H.M. Ni, W. Gao, X. Chen, J.H. Kang, D.B. Stolz, J. Liu, and X.M. Yin Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy Mol. Cancer Ther. 8 2009 2036 2045
49. W.X. Ding, H.M. Ni, W. Gao, T. Yoshimori, D.B. Stolz, D. Ron, and X.M. Yin Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability Am. J. Pathol. 171 2007 513 524
50. B. Fellerhoff, S. Gu, B. Laumbacher, A.G. Nerlich, E.H. Weiss, J. Glas, R. Kopp, J.P. Johnson, and R. Wank The LMP7-K allele of the immunoproteasome exhibits reduced transcript stability and predicts high risk of colon cancer Cancer Res. 71 2011 7145 7154
51. A.E. Finlayson, and K.W. Freeman A cell motility screen reveals role for MARCKS-related protein in adherens junction formation and tumorigenesis PLoS ONE 4 2009 e7833
52. J.I. Fletcher, M. Haber, M.J. Henderson, and M.D. Norris ABC transporters in cancer: more than just drug efflux pumps Nat. Rev. Cancer 10 2010 147 156
53. A. Fraile, A. Nieto, J. Vinasco, Y. Beraun, J. Martin, and L. Mataran Association of large molecular weight proteasome 7 gene polymorphism with ankylosing spondylitis Arthritis Rheum. 41 1998 560 562
54. N.E. Franke, D. Niewerth, Y.G. Assaraf, J. Van Meerloo, K. Vojtekova, C.H. van Zantwijk, S. Zweegman, E.T. Chan, C.J. Kirk, D.P. Geerke, A.D. Schimmer, G.J.L. Kaspers, G. Jansen, and J. Cloos Impaired bortezomib binding to mutant beta5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells Leukemia 26 2012 757 768
55. D. Fuchs, C. Berges, G. Opelz, V. Daniel, and C. Naujokat Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells J. Cell. Biochem. 103 2008 270 283
56. A.K. Gandhi, J. Kang, C.G. Havens, T. Conklin, Y. Ning, L. Wu, T. Ito, H. Ando, M.F. Waldman, A. Thakurta, A. Klippel, H. Handa, T.O. Daniel, P.H. Schafer, and R. Chopra Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN) Br. J. Haematol. 164 2014 811 821
57. E. Gallerani, M. Zucchetti, D. Brunelli, E. Marangon, C. Noberasco, D. Hess, A. Delmonte, G. Martinelli, S. Bohm, C. Driessen, B.F. De, S. Marsoni, R. Cereda, F. Sala, M. D'Incalci, and C. Sessa A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma Eur. J. Cancer 49 2013 290 296
58. L. Garderet, S. Iacobelli, P. Moreau, M. Dib, I. Lafon, D. Niederwieser, T. Masszi, J. Fontan, M. Michallet, A. Gratwohl, G. Milone, C. Doyen, B. Pegourie, R. Hajek, P. Casassus, B. Kolb, C. Chaleteix, B. Hertenstein, F. Onida, H. Ludwig, N. Ketterer, C. Koenecke, M. van Os, M. Mohty, A. Cakana, N.C. Gorin, T. de Witte, J.L. Harousseau, C. Morris, and G. Gahrton Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation J. Clin. Oncol. 30 2012 2475 2482
59. L. Gil, J.A.N. Styczynski, D. Dytfeld, R. Debski, M. Kazmierczak, B. Kolodziej, B. Rafinska, M. Kubicka, A. Nowicki, M. Komarnicki, and M. Wysocki Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia Anticancer Res. 27 2007 4021 4026
60. A.V. Gomes Genetics of proteasome diseases Scientifica (Cairo) 637629 2013
61. T.D. Green, A.L. Crews, J. Park, S. Fang, and K.B. Adler Regulation of mucin secretion and inflammation in asthma: a role for MARCKS protein? Biochim. Biophys. Acta 1810 2011 1110 1113
62. T.A. Griffin, D. Nandi, M. Cruz, H.J. Fehling, L. Kaer, Van, and R.A. Colbert Immunoproteasome assembly: cooperative incorporation of interferon-y (IFNy)-inducible subunits J. Exp. Med. 187 1998 97 104
63. M. Groettrup, C.J. Kirk, and M. Basler Proteasomes in immune cells: more than peptide producers? Nat. Rev. Immunol. 10 2010 73 78
64. T.M. Grogan, C.M. Spier, S.E. Salmon, M. Matzner, J. Rybski, R.S. Weinstein, R.J. Scheper, and W.S. Dalton P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy Blood 81 1993 490 495
65. M. Groll, C.R. Berkers, H.L. Ploegh, and H. Ovaa Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome Structure 14 2006 451 456
66. J. Gu, J. Li, Z. Zhou, J. Liu, B. Huang, D. Zheng, and C. Su Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma Biochem. Biophys. Res. Commun. 420 2012 644 650
67. M. Hao, L. Zhang, G. An, W. Sui, Z. Yu, D. Zou, Y. Xu, H. Chang, and L. Qiu Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells J. Hematol. Oncol. 4 2011 37
68. S. Heink, B. Fricke, D. Ludwig, P.M. Kloetzel, and E. Krüger Tumor cell lines expressing the proteasome subunit isoform LMP7E1 exhibit immunoproteasome deficiency Cancer Res. 66 2006 649 652
69. S. Heink, D. Ludwig, P.M. Kloetzel, and E. Kruger IFN-gamma-induced immune adaptation of the proteasome system is an accelerated and transient response Proc. Natl. Acad. Sci. U. S. A. 102 2005 9241 9246
70. T.M. Herndon, A. Deisseroth, E. Kaminskas, R.C. Kane, K.M. Koti, M.D. Rothmann, B. Habtemariam, J. Bullock, J.D. Bray, J. Hawes, T.R. Palmby, J. Jee, W. Adams, H. Mahayni, J. Brown, A. Dorantes, R. Sridhara, A.T. Farrell, and R. Pazdur U.S. Food and drug administration approval: carfilzomib for the treatment of multiple myeloma Clin. Cancer Res. 19 2013 4559 4563
71. T. Hideshima, J.E. Bradner, J. Wong, D. Chauhan, P. Richardson, S.L. Schreiber, and K.C. Anderson Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma Proc. Natl. Acad. Sci. U. S. A. 102 2005 8567 8572
72. T. Hideshima, L. Catley, N. Raje, D. Chauhan, K. Podar, C. Mitsiades, Y.T. Tai, S. Vallet, T. Kiziltepe, E. Ocio, H. Ikeda, Y. Okawa, H. Hideshima, N.C. Munshi, H. Yasui, P.G. Richardson, and K.C. Anderson Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells Br. J. Haematol. 138 2007 783 791
73. S.M. Hitzerd, S.E. Verbrugge, G. Ossenkoppele, G. Jansen, and G.J. Peters Positioning of aminopeptidase inhibitors in next generation cancer therapy Amino Acids 46 2014 793 808
74. T.M. Horton, D. Pati, S.E. Plon, P.A. Thompson, L.R. Bomgaars, P.C. Adamson, A.M. Ingle, J. Wright, A.H. Brockman, M. Paton, and S.M. Blaney A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study Clin. Cancer Res. 13 2007 1516 1522
75. T.M. Horton, J.P. Perentesis, A.S. Gamis, T.A. Alonzo, R.B. Gerbing, J. Ballard, K. Adlard, D.S. Howard, F.O. Smith, G.J. Schuurhuis, J.A. Moscow, and G. Jenkins A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the children's oncology group Pediatr. Blood Cancer 61 2014 1754 1760
76. D.S. Howard, J. Liesveld, G.L. Phillips, J. Hayslip, H. Weiss, C.T. Jordan, and M.L. Guzman A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia Leuk. Res. 37 2013 1502 1508
77. E.M. Huber, M. Basler, R. Schwab, W. Heinemeyer, C.J. Kirk, M. Groettrup, and M. Groll Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity Cell 148 2012 727 738
78. S. Jagannath, B. Barlogie, J. Berenson, D. Siegel, D. Irwin, P.G. Richardson, R. Niesvizky, R. Alexanian, S.A. Limentani, M. Alsina, J. Adams, M. Kauffman, D.L. Esseltine, D.P. Schenkein, and K.C. Anderson A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma Br. J. Haematol. 127 2004 165 172
79. S. Jagannath, B. Barlogie, J.R. Berenson, D.S. Siegel, D. Irwin, P.G. Richardson, R. Niesvizky, R. Alexanian, S.A. Limentani, M. Alsina, D.L. Esseltine, and K.C. Anderson Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma Br. J. Haematol. 143 2008 537 540
80. A.J. Jakubowiak, D.S. Siegel, T. Martin, M. Wang, R. Vij, S. Lonial, S. Trudel, V. Kukreti, N. Bahlis, M. Alsina, A. Chanan-Khan, F. Buadi, F.J. Reu, G. Somlo, J. Zonder, K. Song, A.K. Stewart, E. Stadtmauer, B.L. Harrison, A.F. Wong, R.Z. Orlowski, and S. Jagannath Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study Leukemia 27 2013 2351 2356
81. L. Jia, G. Gopinathan, J.T. Sukumar, and J.G. Gribben Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells PLoS ONE 7 2012 e32584
82. A. Johnsen, J. France, M. Sy, C. Lines, and C.V. Harding Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines Cancer Res. 58 1998 3660 3667
83. A.J. Kale, R.P. McGlinchey, A. Lechner, and B.S. Moore Bacterial self-resistance to the natural proteasome inhibitor salinosporamide A ACS Chem. Biol. 6 2011 1257 1264
84. A.J. Kale, and B.S. Moore Molecular mechanisms of acquired proteasome inhibitor resistance J. Med. Chem. 55 2012 10317 10327
85. R.C. Kane, P.F. Bross, A.C. Farrell, and R. Padzur Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy Oncologist 8 2003 508 513
86. R.C. Kane, R. Dagher, A. Farrell, C.W. Ko, R. Sridhara, R. Justice, and R. Pazdur Bortezomib for the treatment of mantle cell lymphoma Clin. Cancer Res. 13 2007 5291 5294
87. G.J.L. Kaspers, D. Niewerth, S. Ramnarain, A. Attarbaschi, A. Baruchel, E. de Bont, F. Fagioli, F. Locatelli, B. de Moerloose, K. Nysom, D. Reinhardt, P. Rohrlich, P. Simon, A. von Stackelberg, and C.M. Zwaan Interim results of a feasibility and phase II study on bortezomib (BTZ) in pediatric multiply relapsed or refractory acute lymphoblastic leukemia: complete hematological responses with a modestly intensive regimen including BTZ American Society of Hematology Annual Meeting Abstract, #2290 2014
88. E.Z. Kincaid, J.W. Che, I. York, H. Escobar, E. Reyes-Vargas, J.C. Delgado, R.M. Welsh, M.L. Karow, A.J. Murphy, D.M. Valenzuela, G.D. Yancopoulos, and K.L. Rock Mice completely lacking immunoproteasomes show major changes in antigen presentation Nat. Immunol. 13 2012 129 135
89. C.J. Kirk Discovery and development of second-generation proteasome inhibitors Semin. Hematol. 49 2012 207 214
90. A.F. Kisselev, W.A. van der Linden, and H.S. Overkleeft Proteasome inhibitors: an expanding army attacking a unique target Chem. Biol. 19 2012 99 115
91. A. Kitamura, Y. Maekawa, H. Uehara, K. Izumi, I. Kawachi, M. Nishizawa, Y. Toyoshima, H. Takahashi, D.M. Standley, K. Tanaka, J. Hamazaki, S. Murata, K. Obara, I. Toyoshima, and K. Yasutomo A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans J. Clin. Invest. 121 2011 4150 4160
92. P.M. Kloetzel, and F. Ossendorp Proteasome and peptidase function in MHC-class-I-mediated antigen presentation Curr. Opin. Immunol. 16 2004 76 81
93. A. Kniepert, and M. Groettrup The unique functions of tissue-specific proteasomes Trends Biochem. Sci. 39 2014 17 24
94. D. Komander, M.J. Clague, and S. Urbé Breaking the chains: structure and function of the deubiquitinases Nat. Rev. Mol. Cell Biol. 10 2009 550 563
95. K.M. Kortuem, and A.K. Stewart Carfilzomib. Blood 121 2013 893 897
96. M. Kraus, T. Ruckrich, M. Reich, J. Gogel, A. Beck, W. Kammer, C.R. Berkers, D. Burg, H. Overkleeft, H. Ovaa, and C. Driessen Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells Leukemia 21 2007 84 92
97. J. Krönke, A. Narla, S.N. Hurst, N. Udeshi, Schenone, M.M. McConkey, P. Grauman, D. Heckl, R. McAuley, C. Ciarlo, E. Comer, X. Li, S.A. Carr, and B.L. Ebert Inhibition of the CRBN-DDB1-CUL4-ROC1 E3 ubiquitin ligase mediates the anti-proliferative and immunomodulatory properties of lenalidomide American Society of Hematolgy Annual Meeting Abstract, vol. 120 2012 919
98. J. Krönke, N. Udeshi, A. Narla, P. Grauman, S.N. Hurst, M. McConkey, T. Svinkina, D. Heckl, E. Comer, X. Li, C. Ciarlo, E. Hartman, M. Schenone, S.L. Schreiber, S.A. Carr, and B.L. Ebert Lenalidomide causes selective degradation of IKFZ1 and IKFZ3 in multiple myeloma cells Science 343 2014 301 305
99. D.J. Kuhn, Z. Berkova, R.J. Jones, R. Woessner, C.C. Bjorklund, W. Ma, R.E. Davis, P. Lin, H. Wang, T.L. Madden, C. Wei, V. Baladandayuthapani, M. Wang, S.K. Thomas, J.J. Shah, D.M. Weber, and R.Z. Orlowski Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma Blood 120 2012 3260 3270
100. S.K. Kumar, W.I. Bensinger, T.M. Zimmerman, C.B. Reeder, J.R. Berenson, D. Berg, A.-M. Hui, N. Gupta, A. Di Bacco, J. Yu, Y. Shou, and R. Niesvizky Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma Blood 124 2014 1047 1055
101. A. Kumatori, K. Tanaka, N. Inamura, S. Sone, T. Ogura, T. Matsumoto, T. Tachikawa, S. Shin, and A. Ichihara Abnormally high expression of proteasomes in human leukemic cells Proc. Natl. Acad. Sci. U. S. A. 87 1990 7071 7075
102. E. Kupperman, E.C. Lee, Y. Cao, B. Bannerman, M. Fitzgerald, A. Berger, J. Yu, Y. Yang, P. Hales, F. Bruzzese, J. Liu, J. Blank, K. Garcia, C. Tsu, L. Dick, P. Fleming, L. Yu, M. Manfredi, M. Rolfe, and J. Bolen Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer Cancer Res. 70 2010 1970 1980
103. J.E. Lancet, V.H. Duong, E.F. Winton, R.K. Stuart, M. Burton, S. Zhang, C. Cubitt, M.A. Blaskovich, J.J. Wright, S. Sebti, and D.M. Sullivan A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias Clin. Cancer Res. 17 2011 1140 1146
104. C. Leung-Hagesteijn, N. Erdmann, G. Cheung, J.J. Keats, A.K. Stewart, D.E. Reece, K.C. Chung, and R.E. Tiedemann Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma Cancer Cell 24 2013 289 304
105. B. Li, H. Wang, and R.Z. Orlowski Proteasome maturation protein (POMP) is associated with proteasome inhibitor resistance in myeloma, and its suppression enhances the activity of bortezomib and carfilzomib American Society of Hematology Annual Meeting Abstract, vol. 122 2013 280
106. T. Li, D. Li, J. Sha, P. Sun, and Y. Huang MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells Biochem. Biophys. Res. Commun. 383 2009 280 285
107. D.I. Lichter, H. Danaee, M.D. Pickard, O. Tayber, M. Sintchak, H. Shi, P.G. Richardson, J. Cavenagh, J. Bladé, T. Façon, R. Niesvizky, M. Alsina, W. Dalton, P. Sonneveld, S. Lonial, H. van de Velde, D. Ricci, D.-L. Esseltine, W.L. Trepicchio, G. Mulligan, and K.C. Anderson Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone Blood 120 2012 4513 4516
108. A. Lilienbaum Relationship between the proteasomal system and autophagy Int. J. Biochem. Mol. Biol. 4 2013 1 26
109. S.C.W. Ling, E.K.K. Lau, A. Al-Shabeeb, A. Nikolic, A. Catalano, H. Iland, N. Horvath, P.J. Ho, S. Harrison, S. Fleming, D.E. Joshua, and J.D. Allen Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1 Haematologica 97 2012 64 72
110. Y. Liu, Y. Ramot, A. Torrelo, A.S. Paller, N. Si, S. Babay, P.W. Kim, A. Sheikh, C.C.R. Lee, Y. Chen, A. Vera, X. Zhang, R. Goldbach-Mansky, and A. Zlotogorski Mutations in proteasome subunit β type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity Arthritis Rheum. 64 2012 895 907
111. A. Lopez-Girona, D. Heintel, L.H. Zhang, D. Mendy, S. Gaidarova, H. Brady, J.B. Bartlett, P.H. Schafer, M. Schreder, A. Bolomsky, B. Hilgarth, N. Zojer, H. Gisslinger, H. Ludwig, T. Daniel, U. Jäger, and R. Chopra Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response Br. J. Haematol. 154 2011 325 336
112. S. Lu, Z. Chen, J. Yang, L. Chen, S. Gong, H. Zhou, L. Guo, and J. Wang Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line Exp. Hematol. 36 2008 1278 1284
113. S. Lü, Z. Chen, J. Yang, L. Chen, H. Zhou, X. Xu, J. Li, F. Han, and J. Wang The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02 Int. J. Lab. Hematol. 32 2010 e123 e131
114. S. Lu, J. Yang, Z. Chen, S. Gong, H. Zhou, X. Xu, and J. Wang Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line Exp. Hematol. 37 2009 831 837
115. S. Lu, J. Yang, X. Song, S. Gong, H. Zhou, L. Guo, N. Song, X. Bao, P. Chen, and J. Wang Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line J. Pharmacol. Exp. Ther. 326 2008 423 431
116. H. Ludwig, H. Kasparu, C. Leitgeb, E. Rauch, W. Linkesch, N. Zojer, R. Greil, A. Seebacher, L. Pour, A. Weissman, and Z. Adam Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed multiple myeloma Blood 123 2014 985 991
117. S. Markovina, N.S. Callander, S.L. O'Connor, J. Kim, J.E. Werndli, M. Raschko, C.P. Leith, B.S. Kahl, K. Kim, and S. Miyamoto Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells Mol. Cancer Res. 6 2008 1356 1364
118. F. Mattiroli, and T. Sixma Lysine-targeting specificity in ubiquitin and ubiquitin-like modification pathways Nat. Struct. Biol. 21 2014 308 316
119. A. McBride, and P.Y. Ryan Proteasome inhibitors in the treatment of multiple myeloma Expert Rev. Anticancer Ther. 13 2013 339 358
120. D.J. McConkey, and K. Zhu Mechanisms of proteasome inhibitor action and resistance in cancer Drug Resist. Updates 11 2008 164 179
121. D.J. McConkey, M. White, and W. Yan HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer Adv. Cancer Res. 116 2012 131 163
122. S. Meister, U. Schubert, K. Neubert, K. Herrmann, R. Burger, M. Gramatzki, S. Hahn, S. Schreiber, S. Wilhelm, M. Herrmann, H.M. Jäck, and R.E. Voll Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition Cancer Res. 67 2007 1783 1792
123. Y. Messinger, P. Gaynon, E. Raetz, R. Hutchinson, S. Dubois, J. Glade-Bender, R. Sposto, G.J. van der, E. Eckroth, and B.C. Bostrom Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium Pediatr. Blood Cancer 55 2010 254 259
124. Y.H. Messinger, P.S. Gaynon, R. Sposto, J. van der Giessen, E. Eckroth, J. Malvar, and B.C. Bostrom Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: therapeutic advances in childhood leukemia and lymphoma (TACL) study Blood 120 2012 285 290
125. M.B. Metzger, J.N. Pruneda, R.E. Klevit, and A.M. Weissman RING-type E3 ligases: master manipulators of E2 ubiquitin-conjugating enzymes and ubiquitination Biochim. Biophys. Acta 1843 2014 47 60
126. J. Micallef, M. Taccone, J. Mukherjee, S. Croul, J. Busby, M.F. Moran, and A. Guha Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression Cancer Res. 69 2009 7548 7556
127. M. Milani, T. Rzymski, H.R. Mellor, L. Pike, A. Bottini, D. Generali, and A.L. Harris The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib Cancer Res. 69 2009 4415 4423
128. C.P. Miller, K. Ban, M.E. Dujka, D.J. McConkey, M. Munsell, M. Palladino, and J. Chandra NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells Blood 110 2007 267 277
129. N. Mimura, M. Fulciniti, G. Gorgun, Y.T. Tai, D. Cirstea, L. Santo, Y. Hu, C. Fabre, J. Minami, H. Ohguchi, T. Kiziltepe, H. Ikeda, Y. Kawano, M. French, M. Blumenthal, V. Tam, N.L. Kertesz, U.M. Malyankar, M. Hokenson, T. Pham, Q. Zeng, J.B. Patterson, P.G. Richardson, N.C. Munshi, and K.C. Anderson Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma Blood 119 2012 5772 5781
130. H. Minderman, Y. Zhou, K.L. O'Loughlin, and M.R. Baer Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status Cancer Chemother. Pharmacol. 60 2007 245 255
131. P. Moreau, H. Pylypenko, S. Grosicki, I. Karamanesht, X. Leleu, M. Grishunina, G. Rekhtman, Z. Masliak, T. Robak, A. Shubina, B. Arnulf, M. Kropff, J. Cavet, D.L. Esseltine, H. Feng, S. Girgis, H. van Velde, W. Deraedt, and J.L. Harousseau Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study Lancet Oncol. 12 2011 431 440
132. T. Muchamuel, M. Basler, M.A. Aujay, E. Suzuki, K.W. Kalim, C. Lauer, C. Sylvain, E.R. Ring, J. Shields, J. Jiang, P. Shwonek, F. Parlati, S.D. Demo, M.K. Bennett, C.J. Kirk, and M. Groettrup A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis Nat. Med. 15 2009 781 787
133. S. Murata, H. Yashiroda, and K. Tanaka Molecular mechanisms of proteasome assembly Nat. Rev. Mol. Cell Biol. 10 2009 104 115
134. J.A. Nathan, H.T. Kim, L. Ting, S.P. Gygi, and A.L. Goldberg Why do cellular proteins linked to K63-polyubiquitin chains not associate with proteasomes? EMBO J. 32 2013 552 565
135. J.A. Nathan, V. Spinnenhirn, G. Schmidtke, M. Basler, M. Groettrup, and A.L. Goldberg Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins Cell 152 2013 1184 1194
136. R. Niesvizky, T.G. Martin, W.I. Bensinger, M. Alsina, D.S. Siegel, L.A. Kunkel, A.F. Wong, S. Lee, R.Z. Orlowski, and M. Wang Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma Clin. Cancer Res. 19 2013 2248 2256
137. D. Niewerth, I. Dingjan, J. Cloos, G. Jansen, and G.J.L. Kaspers Proteasome inhibitors in acute leukemia Expert Rev. Anticancer Ther. 13 2013 327 337
138. D. Niewerth, N.E. Franke, G. Jansen, Y.G. Assaraf, J. van Meerloo, C.J. Kirk, J. Degenhardt, J.L. Anderl, A.D. Schimmer, V. de Haas, T.M. Horton, S. Zweegman, G.J.L. Kaspers, and J. Cloos Higher ratio immune vs. constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors Haematologica 98 2013 1896 1904
139. D. Niewerth, G. Jansen, L.F.V. Riethoff, J. van Meerloo, A.J. Kale, B.S. Moore, Y.G. Assaraf, J.L. Anderl, S. Zweegman, G.J.L. Kaspers, and J. Cloos Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib) Mol. Pharmacol. 86 2014 12 19
140. D. Niewerth, G.J.L. Kaspers, Y.G. Assaraf, J. van Meerloo, C.J. Kirk, J.A. Anderl, J.L. Blank, P.M. van der Ven, S. Zweegman, G. Jansen, and J. Cloos Interferon-y-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines J. Hematol. Oncol. 7 2014 7
141. D. Niewerth, J. van Meerloo, Y.G. Assaraf, G. Jansen, T.C. Hendrickx, C.J. Kirk, J.L. Anderl, S. Zweegman, J. Cloos, and G.J. Kaspers Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924 Biochem. Pharmacol. 89 2014 43 51
142. R. O'Connor, M.G. Ooi, J. Meiller, J. Jakubikova, S. Klippel, J. Delmore, P. Richardson, K. Anderson, M. Clynes, C.S. Mitsiades, and P. O'Gorman The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias Cancer Chemother. Pharmacol. 71 2013 1357 1368
143. E.A. Obeng, L.M. Carlson, D.M. Gutman, W.J. Harrington, K.P. Lee, and L.H. Boise Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells Blood 107 2006 4907 4916
144. R. Oerlemans, N.E. Franke, Y.G. Assaraf, J. Cloos, I. van Zantwijk, C.R. Berkers, G.L. Scheffer, K. Debipersad, K. Vojtekova, C. Lemos, J.W. van der Heijden, B. Ylstra, G.J. Peters, G.J.L. Kaspers, B.A. Dijkmans, R.J. Scheper, and G. Jansen Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein Blood 112 2008 2489 2499
145. R.Z. Orlowski, and D.J. Kuhn Proteasome inhibitors in cancer therapy: lessons from the first decade Clin. Cancer Res. 14 2008 1649 1657
146. R.Z. Orlowski, A. Nagler, P. Sonneveld, J. Bladé, R. Hajek, A. Spencer, J. San Miguel, T. Robak, A. Dmoszynska, N. Horvath, I. Spicka, H.J. Sutherland, A.N. Suvorov, S.H. Zhuang, T. Parekh, L. Xiu, Z. Yuan, W. Rackoff, and J.L. Harousseau Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression J. Clin. Oncol. 25 2007 3892 3901
147. F. Parlati, S.J. Lee, M. Aujay, E. Suzuki, K. Levitsky, J.B. Lorens, D.R. Micklem, P. Ruurs, C. Sylvain, Y. Lu, K.D. Shenk, and M.K. Bennett Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome Blood 114 2009 3439 3447
148. P. Pérez-Galán, H. Mora-Jensen, M.A. Weniger, A.L. Shaffer, E.G. Rizzatti, C.M. Chapman, C.C. Mo, L.S. Stennett, C. Rader, P. Liu, N. Raghavachari, M. Stetler-Stevenson, C. Yuan, S. Pittaluga, I. Maric, K.M. Dunleavy, W.H. Wilson, L.M. Staudt, and A. Wiestner Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation Blood 117 2011 542 552
149. P. Pérez-Galán, G. Roué, N. Villamor, E. Montserrat, E. Campo, and D. Colomer The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status Blood 107 2006 257 264
150. M.T. Petrucci, P. Giraldo, P. Corradini, A. Teixeira, M.A. Dimopoulos, I.W. Blau, J. Drach, R. Angermund, N. Allietta, E. Broer, V. Mitchell, and J. Bladé A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma Br. J. Haematol. 160 2013 649 659
151. K. Podar, D. Chauhan, and K.C. Anderson Bone marrow microenvironment and the identification of new targets for myeloma therapy Leukemia 23 2009 10 24
152. M. Politou, A. Karadimitris, E. Terpos, I. Kotsianidis, J.F. Apperley, and A. Rahemtulla No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib Leuk. Res. 30 2006 240 241
153. B.C. Potts, M.X. Albitar, K.C. Anderson, S. Baritaki, C. Berkers, B. Bonavida, J. Chandra, D. Chauhan, J.C. Cusack, W. Fenical, I.M. Ghobrial, M. Groll, P.R. Jensen, K.S. Lam, G.K. Lloyd, W. McBride, D.J. McConkey, C.P. Miller, S.T.C. Neuteboom, Y. Oki, H. Ovaa, F. Pajonk, P.G. Richardson, A.M. Roccaro, C.M. Sloss, M.A. Spear, E. Valashi, A. Younes, and M.A. Palladino Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials Curr. Cancer Drug Targets 11 2011 254 284
154. S. Prahalad, D.J. Kingsbury, T.A. Griffin, B. Cooper, D.N. Glass, W.P. Maksymowych, and R.A. Colbert Polymorphism in the MHC-encoded LMP7 Gene: association with JRA without Functional Significance for Immunoproteasome Assembly J. Rheumatol. 28 2001 2320 2325
155. M. Raule, F. Cerruti, and P. Cascio Enhanced rate of degradation of basic proteins by 26S immunoproteasomes Biochim. Biophys. Acta 1843 2014 1942 1947
156. A.M. Reimold, N.N. Iwakoshi, J. Manis, P. Vallabhajosyula, E. Szomolanyi-Tsuda, E.M. Gravallese, D. Friend, M.J. Grusby, F. Alt, and L.H. Glimcher Plasma cell differentiation requires the transcription factor XBP-1 Nature 412 2001 300 307
157. E.A. Reits, A.M. Benham, B. Plougastel, J. Neefjes, and J. Trowsdale Dynamics of proteasome distribution in living cells EMBO J. 16 1997 6087 6094
158. E. Reits, A. Griekspoor, J. Neijssen, T. Groothuis, K. Jalink, P. van Veelen, H. Janssen, J. Calafat, J.W. Drijfhout, and J. Neefjes Peptide diffusion, protection, anddegradation in nuclear and cytoplasmic compartments before antigen presentationby MHC class I Immunity 18 2003 97 108
159. M. Ri, S. Iida, T. Nakashima, H. Miyazaki, F. Mori, A. Ito, A. Inagaki, S. Kusumoto, T. Ishida, H. Komatsu, Y. Shiotsu, and R. Ueda Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress Leukemia 24 2010 1506 1512
160. P.G. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, S.V. Rajkumar, G. Srkalovic, M. Alsina, R. Alexanian, D. Siegel, R.Z. Orlowski, D. Kuter, S.A. Limentani, S. Lee, T. Hideshima, D.L. Esseltine, M. Kauffman, J. Adams, D.P. Schenkein, and K.C. Anderson A phase 2 study of bortezomib in relapsed, refractory myeloma N. Engl. J. Med. 348 2003 2609 2617
161. P.G. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D.H. Irwin, S.V. Rajkumar, G. Srkalovic, M. Alsina, and K.C. Anderson Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial Cancer 106 2006 1316 1319
162. P.G. Richardson, C.C. Hofmeister, C.A. Rosenbaum, M. Htut, D.H. Vesole, J. Berdeja, M. Liedtke, A. Chari, S.D. Smith, D. Lebovic, D. Berg, E. Liao, N. Gupta, A. Di Bacco, J. Estevam, A.M. Hui, and R. Baz Twice-weekly oral MLN9708 (Ixazomib citrate), an investigational proteasome inhibitor, in combination with lenalidomide (Len) and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): final phase 1 results and phase 2 data American Society of Hematology Annual Meeting Abstract, vol. 122 2013 535
163. P.G. Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. Harousseau, D. Ben-yehuda, S. Lonial, H. Goldschmidt, D. Reece, J.S. Miguel, A. Jakubowiak, W. Dalton, A. Boral, D. Esseltine, D. Schenkein, and K.C. Anderson Brief report Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial Blood 110 2007 3557 3560
164. P.G. Richardson, P. Sonneveld, M.W. Schuster, D. Irwin, E.A. Stadtmauer, T. Facon, J.L. Harousseau, D. Ben-Yehuda, S. Lonial, H. Goldschmidt, D. Reece, J.F. San-Miguel, J. Bladé, M. Boccadoro, J. Cavenagh, W.S. Dalton, A.L. Boral, D.L. Esseltine, J.B. Porter, D. Schenkein, and K.C. Anderson Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N. Engl. J. Med. 352 2005 2487 2498
165. P.G. Richardson, A. Spencer, P. Cannell, S.J. Harrison, L. Catley, C. Underhill, T.M. Zimmerman, C.C. Hofmeister, A.J. Jakubowiak, J.P. Laubach, M.A. Palladino, A.M. Longenecker, A. Lay, S. Wear, G.K. Lloyd, A.L. Hannah, S. Reich, M.A. Spear, and K.C. Anderson Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma (MM) American Society of Hematology Annual Meeting Abstract, vol. 118 2011 302
166. P.G. Richardson, W. Xie, S. Jagannath, A. Jakubowiak, S. Lonial, N.S. Raje, M. Alsina, I.M. Ghobrial, R.L. Schlossman, N.C. Munshi, A. Mazumder, D.H. Vesole, J.L. Kaufman, K. Colson, M. McKenney, L.E. Lunde, J. Feather, M.E. Maglio, D. Warren, D. Francis, T. Hideshima, R. Knight, D.-L. Esseltine, C.S. Mitsiades, E. Weller, and K.C. Anderson A phase II trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed and relapsed/refractory myeloma Blood 123 2014 1461 1469
167. A.M. Roccaro, A. Sacco, M. Aujay, H.T. Ngo, A.K. Azab, F. Azab, P. Quang, P. Maiso, J. Runnels, K.C. Anderson, S. Demo, and I.M. Ghobrial Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia Blood 115 2010 4051 4060
168. K.L. Rock, I.A. York, T. Saric, and A.L. Goldberg Protein degradation and the generation of MHC class I-presented peptides Adv. Immunol. 80 2002 1 70
169. A. Romano, A. Chiarenza, C. Conticello, M. Cavali, C. Vetro, C. Di Raimondo, G.A. Palumbo, and F. Di Raimondo Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients Eur. J. Haematol. 93 2014 207 213
170. D. Ron, and P. Walter Signal integration in the endoplasmic reticulum unfolded protein response Nat. Rev. Mol. Cell Biol. 8 2007 519 529
171. T. Ruckrich, M. Kraus, J. Gogel, A. Beck, H. Ovaa, M. Verdoes, H.S. Overkleeft, H. Kalbacher, and C. Driessen Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells Leukemia 23 2009 1098 1105
172. H. Rumpold, C. Salvador, A.M. Wolf, H. Tilg, G. Gastl, and D. Wolf Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors Biochem. Biophys. Res. Commun. 361 2007 549 554
173. J.F. San-Miguel, V.T.M. Hungria, S.S. Yoon, M. Beksac, M.A. Dimopoulos, A. Elghandour, W.W. Jedrzejczak, A. Günther, T.N. Nakorn, N. Siritanaratkul, P. Corradini, S. Chuncharunee, J.J. Lee, R.L. Schlossman, T. Shelekhova, K. Yong, D. Tan, T. Numbenjapon, J.D. Cavenagh, J. Hou, R. LeBlanc, H. Nahi, L. Qiu, H. Salwender, S. Pulini, P. Moreau, K. Warzocha, D. White, J. Bladé, W. Chen, J. de la Rubia, P. Gimsing, S. Lonial, J.L. Kaufman, E.M. Ocio, L. Veskovski, S.K. Sohn, M.C. Wang, J.H. Lee, H. Einsele, M. Sopala, C. Corrado, B.R. Bengoudifa, F. Binlich, and P.G. Richardson Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial Lancet Oncol. 15 2014 1195 1206
174. J.F. San-Miguel, and M.V. Mateos Can multiple myeloma become a curable disease? Haematologica 96 2011 1246 1248
175. C. Sarlo, F. Buccisano, L. Maurillo, M. Cefalo, L. Di Caprio, L. Cicconi, C. Ditto, L. Ottaviani, A. Di Veroli, M. Ilaria, D. Principe, M.A. Grasso, D. Nasso, G. De Santis, and S. Amadori Phase II Study of bortezomib as a single agent in patients with previously untreated or relapsed/refractory acute myeloid leukemia ineligible for intensive therapy Leuk. Res. Treat. 2013 2013 705714
176. M. Schaich, S. Soucek, C. Thiede, G. Ehninger, and T. Illmer MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia Br. J. Haematol. 128 2005 324 332
177. S.M. Schmitt, R.R. Deshmukh, and Q.P. Dou Proteasome inhibitors and lessons learned from their mechanisms of action and resistance in human cancer Q.P. Dou, Resistance to Proteasome Inhibitors in Cancer 2014 Springer International Publishing Switzerland 1 46
178. U. Schubert, L.C. Antón, J. Gibbs, C.C. Norbury, J.W. Yewdell, and J.R. Bennink Rapid degradation of a large fraction of newly synthesized proteins by proteasomes Nature 404 2000 770 774
179. U. Seifert, L.P. Bialy, F. Ebstein, D. Bech-Otschir, A. Voigt, F. Schroter, T. Prozorovski, N. Lange, J. Steffen, M. Rieger, U. Kuckelkorn, O. Aktas, P.M. Kloetzel, and E. Kruger Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress Cell 142 2010 613 624
180. R.A. Shah, S.K. Thomas, D.M. Weber, M. Wang, R. Alexanian, R.Z. Orlowski, and J.J. Shah Feasibility and activity of bortezomib-based therapy in patients with relapsed/refractory multiple myeloma previously treated with carfilzomib American Society of Hematology Annual Meeting Abstract, vol. 122 2013 1994
181. L. Shuqing, Y. Jianmin, H. Chongmei, C. Hui, and J. Wang Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen Exp. Hematol. 39 2011 1117 1118
182. D.S. Siegel, T. Martin, M. Wang, R. Vij, A.J. Jakubowiak, S. Lonial, S. Trudel, V. Kukreti, N. Bahlis, M. Alsina, A. Chanan-Khan, F. Buadi, F.J. Reu, G. Somlo, J. Zonder, K. Song, A.K. Stewart, E. Stadtmauer, L. Kunkel, S. Wear, A.F. Wong, R.Z. Orlowski, and S. Jagannath A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma Blood 120 2012 2817 2825
183. A.V. Singh, M. Bandi, M.A. Aujay, C.J. Kirk, D.E. Hark, N. Raje, D. Chauhan, and K.C. Anderson PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo Br. J. Haematol. 152 2011 155 163
184. R. Sood, H. Carloss, R. Kerr, J. Lopez, M. Lee, M. Druck, I.B. Walters, and S.J. Noga Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib Am. J. Hematol. 84 2009 657 660
185. T.A. Soucy, P.G. Smith, M.A. Milhollen, A.J. Berger, J.M. Gavin, S. Adhikari, J.E. Brownell, K.E. Burke, D.P. Cardin, S. Critchley, C.A. Cullis, A. Doucette, J.J. Garnsey, J.L. Gaulin, R.E. Gershman, A.R. Lublinsky, A. McDonald, H. Mizutani, U. Narayanan, E.J. Olhava, S. Peluso, M. Rezaei, M.D. Sintchak, T. Talreja, M.P. Thomas, T. Traore, S. Vyskocil, G.S. Weatherhead, J. Yu, J. Zhang, L.R. Dick, C.F. Claiborne, M. Rolfe, J.B. Bolen, and S.P. Langston An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer Nature 458 2009 732 736
186. A.C. Sprynski, D. Hose, L. Caillot, T. Re, J.D.S. Jr, B. Barlogie, M. Hundemer, M. Jourdan, T. Meißner, A. Jauch, A. Kassambara, U. Bertsch, J. Franc, H. Goldschmidt, and B. Klein The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor Lymphoid Neoplasia 113 2009 4614 4626
187. F.C. Streich, and C.D. Lima Structural and functional insights to ubiquitin-like protein conjugation Annu. Rev. Biophys. 43 2014 357 379
188. E. Suzuki, S. Demo, E. Deu, J. Keats, S. Rastu-Kapur, P.L. Bergsagel, M.K. Bennett, and C.J. Kirk Molecular mechanisms of bortezomib resistant adenocarcinoma cells PLoS ONE 6 2011 e27996
189. R.T. Swords, K.R. Kelly, P.G. Smith, J.J. Garnsey, D. Mahalingam, E. Medina, K. Oberheu, S. Padmanabhan, M. O'Dwyer, S.T. Nawrocki, F.J. Giles, and J.S. Carew Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia Blood 115 2010 3796 3800
190. Z. Tian, P. D'Arcy, X. Wang, A. Ray, Y.-T. Tai, Y. Hu, R.D. Carrasco, P. Richardson, S. Linder, D. Chauhan, and K.C. Anderson A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance Blood 123 2014 706 716
191. S. van Deventer, and J. Neefjes The immunoproteasome cleans up after inflammation Cell 142 2010 517 518
192. S.E. Verbrugge, M. Al, Y.G. Assaraf, D. Niewerth, J. van Meerloo, J. Cloos, M. van der Veer, G.L. Scheffer, G.J. Peters, E.T. Chan, J.L. Anderl, C.J. Kirk, S. Zweegman, B.A. Dijkmans, W.F. Lems, R.J. Scheper, T.D. de Gruijl, and G. Jansen Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors Exp. Hematol. Oncol. 2 2013 2
193. S.E. Verbrugge, Y.G. Assaraf, B.A. Dijkmans, G.L. Scheffer, M. Al, D. Den Uyl, R. Oerlemans, E.T. Chan, C.J. Kirk, G.J. Peters, J.W. van der Heijden, T.D. de Gruijl, R.J. Scheper, and G. Jansen Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis J. Pharmacol. Exp. Ther. 341 2012 174 182
194. N. Vigneron, and B.J. Van den Eynde Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity Curr. Opin. Hematol. 24 2012 84 91
195. R. Vij, D.S. Siegel, S. Jagannath, A.J. Jakubowiak, A.K. Stewart, K. Mcdonagh, N. Bahlis, A. Belch, L.A. Kunkel, S. Wear, A.F. Wong, and R.Z. Orlowski Carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib Br. J. Haematol. 158 2012 739 748
196. R. Vij, M. Wang, J.L. Kaufman, S. Lonial, A.J. Jakubowiak, A.K. Stewart, V. Kukreti, S. Jagannath, K.T. Mcdonagh, M. Alsina, N.J. Bahlis, F.J. Reu, N.Y. Gabrail, A. Belch, J.V. Matous, P. Lee, P. Rosen, M. Sebag, D.H. Vesole, L.A. Kunkel, S.M. Wear, A.F. Wong, R.Z. Orlowski, and D.S. Siegel Carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma Blood 119 2012 5661 5670
197. P.M. Voorhees, R.F. Manges, P. Sonneveld, S. Jagannath, G. Somlo, A. Krishnan, S. Lentzsch, R.C. Frank, S. Zweegman, P.W. Wijermans, R.Z. Orlowski, B. Kranenburg, B. Hall, T. Casneuf, X. Qin, H. van de Velde, H. Xie, and S.K. Thomas A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma Br. J. Haematol. 161 2013 357 366
198. R.B. Walter, T.A. Gooley, V.H.J. van der Velden, M.R. Loken, J.J.M. van Dongen, D.A. Flowers, I.D. Bernstein, and F.R. Appelbaum CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy Blood 109 2007 4168 4170
199. J. Wang, A. Hendrix, S. Hernot, M. Lemaire, E. De Bruyne, E. Van Valckenborgh, T. Lahoutte, O. De Wever, K. Vanderkerken, and E. Menu Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells Blood 124 2014 555 566
200. L. Wang, S. Kumar, B.L. Fridley, K.R. Kalari, I. Moon, L.L. Pelleymounter, M.A.T. Hildebrandt, A. Batzler, B. Eckloff, E.D. Wieben, and P.R. Greipp Proteasome B subunit pharmacogenomics: gene resequencing and functional genomics Clin. Cancer Res. 14 2008 3503 3513
201. M. Wang, T. Martin, W. Bensinger, M. Alsina, D.S. Siegel, E. Kavalerchik, M. Huang, R.Z. Orlowski, and R. Niesvizky Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma Blood 122 2013 3122 3128
202. E. White, and R.S. DiPaola The double-edged sword of autophagy modulation in cancer Clin. Cancer Res. 15 2009 5308 5316
203. K. Wiberg, K. Carlson, A. Aleskog, R. Larsson, P. Nygren, and E. Lindhagen In vitro activity of bortezomib in cultures of patient tumour cells-potential utility in haematological malignancies Med. Oncol. 26 2009 193 201
204. K. Yamazaki, T. Miyamae, and S. Yokota PW02-024 - a case of candle syndrome treated with thalidomide Pediatr. Rheumatol. 11 2013 A164
205. Y. Yang, Y. Chen, M.N. Saha, J. Chen, K. Evans, L. Qiu, D. Reece, G. An Chen, and H. Chang Targeting phospho-MARCKS overcomes drug resistance and induces antitumor activity in preclinical models of Multiple Myeloma Leukemia 2014 1 33 (Epub)
206. J.W. Yewdell, and C.V. Nicchitta The DRiP hypothesis decennial: support, controversy, refinement and extension Trends Immunol. 27 2006 368 373
207. Y. Zang, S.M. Thomas, E.T. Chan, C.J. Kirk, M.L. Freilino, H.M. DeLancey, J.R. Grandis, C. Li, and D.E. Johnson Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy Clin. Cancer Res. 18 2012 5639 5649
208. K. Zhang, and R.J. Kaufman From endoplasmic-reticulum stress to the inflammatory response Nature 454 2008 455 462
209. H. Zhou, M.A. Aujay, M.K. Bennett, M. Dajee, S.D. Demo, Y. Fang, M.N. Ho, J. Jiang, C.J. Kirk, G.J. Laidig, E.R. Lewis, Y. Lu, T. Muchamuel, F. Parlati, E. Ring, K.D. Shenk, J. Shields, P.J. Shwonek, T. Stanton, C.M. Sun, C. Sylvain, T.M. Woo, and J. Yang Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasomeinhibitor (PR-047) J. Med. Chem. 52 2009 3028 3038
210. K. Zhu, K. Dunner, and D.J. McConkey Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells Oncogene 29 2010 451 462